Eruptive keratoacanthomas associated with pembrolizumab therapy

JAMA Dermatology

Volumn 153, Issue 7, 2017, Pages 694-697

  Freites Martinez, Azael ^a   Kwong, Bernice Y ^b   Rieger, Kerri E ^b   Coit, Daniel G ^a   Colevas, A Dimitrios ^c   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CLOBETASOL; IPILIMUMAB; METHOTREXATE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TRIAMCINOLONE; VEMURAFENIB; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

AGED; ARTICLE; B LYMPHOCYTE; CASE REPORT; CRYOSURGERY; ERUPTIVE KERATOACANTHOMA; FEMALE; HUMAN; KERATOACANTHOMA; LICHEN PLANUS; LICHENOID ERUPTION; MALE; METASTATIC MELANOMA; PRIORITY JOURNAL; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; VERY ELDERLY; BIOPSY; CHEMICALLY INDUCED; FOLLOW UP; NEOPLASMS; PATHOLOGY; PROCEDURES; TIME FACTOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOPSY; CLOBETASOL; CRYOSURGERY; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KERATOACANTHOMA; MALE; NEOPLASMS; TIME FACTORS; TRIAMCINOLONE;

EID: 85024125309     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2017.0989     Document Type: Article

References (15)

1. Kwiek B, Schwartz RA. Keratoacanthoma (KA): an update and review. J AmAcad Dermatol. 2016;74 (6):1220-1233.
2. TidwellWJ, Malone J, Callen JP. Eruptive keratoacanthomas associated with leflunomide. JAMA Dermatol. 2016;152(1):105-106.
3. Lacouture ME, Morris JC, Lawrence DP, et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor α by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother. 2015;64(4):437-446.
4. Aasi S, Silkiss R, Tang JY, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013;149(2):242-243.
5. Belum VR, Rosen AC, Jaimes N, et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2015;121(1):60-68.
6. SanlorenzoM, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206-1212.
7. Hwang SJ, Carlos G,Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J AmAcad Dermatol. 2016;74(3):455-461.e1.
8. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G,Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4): 886-894.
9. Nofal A, Assaf M, Nofal E, Alradi M. Generalized eruptive keratoacanthoma: proposed diagnostic criteria and therapeutic evaluation. J Eur Acad Dermatol Venereol. 2014;28(4):397-404.
10. Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18-22.
11. Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10): 1128-1136.
12. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45-51.
13. Wu TP, Miller K, Cohen DE, Stein JA. Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin. J AmAcad Dermatol. 2013;69(3):426-430.
14. Sanders S, Busam KJ, Halpern AC, Nehal KS. Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy. Dermatol Surg. 2002;28 (10):954-958.
15. Pasquali P, Freites-Martinez A, Fortuno-Mar A. Use of cryobiopsy in dermatological practice. J Am Acad Dermatol. 2015;72(2):e63-e64.